Home Alzheimer’s Disease Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC

Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center in Philadelphia, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib (Inlyta) and pembrolizumab (Keytruda) over sunitinib (Sutent) in the updated analysis of KEYNOTE-426 presented at the 2020 ASCO Virtual Scientific Program.

Transcription:

The most interesting to me is the overall survival endpoint. This continued to show significant benefit to axitinib and pembrolizumab over sunitinib despite the fact that many of the patients on the sunitinib arm were able to access subsequent immunotherapy. We talk about subsequent therapy a bit and as the study matures, more and more patients will come off of their primary therapy and move on to subsequent therapy. There was a large proportion of patients who did not receive subsequent therapy, but one of the points I made in…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Recent Comments